Single agent treatment with a human monoclonal anti-CLDN4 antibody (4D3, Table 1), resulted in moderate effects on in vitro cell growth inhibition across bladder, CRC, gastric, pancreatic or breast cancer cells (48–51, 68). Here, CLDN4 is linked to breast cancer.